Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database

BackgroundThiazolidinediones (TZDs), rosiglitazone (RGZ) and pioglitazone (PGZ) are widely used as hypoglycemic drugs in patients with type 2 diabetes mellitus. The aim of our study was to investigate the profile of adverse drug reactions (ADRs) related to TZDs and to investigate potential risk factors of these ADRs.MethodsType 2 diabetic patients were identified from the French Database of PharmacoVigilance (FPVD) between 2002 and 2006. We investigated ADR related to TZD, focusing on 4 ADR: edema, heart failure, myocardial infarction and hepatitis corresponding to specific WHO-ART terms.ResultsAmong a total of 99,284 adult patients in the FPVD, 2295 reports concerned type 2 diabetic patients (2.3% of the whole database), with 161 (7%) exposed to TZDs. The frequency of edema and cardiac failure was significantly higher with TZDs than in other patients (18% and 7.4% versus 0.8% and 0.1% respectively, p < 0.001) whereas the frequency of hepatitis was similar (5.9% versus 4%, NS). A multiple logistic regression model taking into account potential confounding factors (age, gender, drug exposure and co-morbidities) found that TZD exposure remained associated with heart failure and edema, but not with hepatitis or myocardial infarction.ConclusionsThiazolidinediones exposure is associated with an increased risk of edema and heart failure in patients with type 2 diabetes even when recommendations for use are respected. In contrast, the risk of hepatic reactions and myocardial infarction with this class of drugs seems to be similar to other hypoglycemic agents.

[1]  F. McAlister,et al.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review , 2007, BMJ : British Medical Journal.

[2]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[3]  S. Nissen,et al.  An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality , 2010 .

[4]  M. Lapeyre-Mestre,et al.  Non‐steroidal anti‐inflammatory drug‐related hepatic damage in France and Spain: analysis from national spontaneous reporting systems , 2006, Fundamental & clinical pharmacology.

[5]  D. Hosmer,et al.  A review of goodness of fit statistics for use in the development of logistic regression models. , 1982, American journal of epidemiology.

[6]  Bernard Bégaud,et al.  Rates of spontaneous reporting of adverse drug reactions in France. , 2002, JAMA.

[7]  P. Raskin,et al.  A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. , 2001, Diabetes care.

[8]  A. Fagot-Campagna,et al.  French medical practice in type 2 diabetes: the need for better control of cardiovascular risk factors. , 2008, Diabetes & metabolism.

[9]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[10]  Yoon K Loke,et al.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.

[11]  M. Lapeyre-Mestre,et al.  Prise en charge thérapeutique des patients diabétiques en France : Apport de la Banque Nationale de Pharmacovigilance , 2007 .

[12]  Tara Gomes,et al.  Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. , 2007, JAMA.

[13]  S. Nissen,et al.  Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. , 2010, Archives of internal medicine.

[14]  M. Lapeyre-Mestre,et al.  Risk of Serious Extrapyramidal Symptoms in Patients With Parkinson's Disease Receiving Antidepressant Drugs: A Pharmacoepidemiologic Study Comparing Serotonin Reuptake Inhibitors and Other Antidepressant Drugs , 2003, Clinical neuropharmacology.

[15]  Alfonso T. Perez,et al.  Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone , 2005, Diabetes, obesity & metabolism.

[16]  P. Lurie,et al.  Case series of liver failure associated with rosiglitazone and pioglitazone , 2009, Pharmacoepidemiology and drug safety.

[17]  K. Belton,et al.  Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union , 1997, European Journal of Clinical Pharmacology.

[18]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[19]  F. Schmidt.  Meta-Analysis , 2008 .

[20]  B Bégaud,et al.  Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France , 1985 .

[21]  C. Furberg,et al.  Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis , 2009, Canadian Medical Association Journal.

[22]  Nancee V. Niemeyer,et al.  Thiazolidinedione‐Induced Edema , 2002, Pharmacotherapy.

[23]  Rita Ouellet-Hellstrom,et al.  Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. , 2010, JAMA.

[24]  J Jouglard,et al.  [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. , 1985, Therapie.

[25]  G. Oster,et al.  Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. , 2003, Diabetes care.

[26]  Frantz Thiessard,et al.  Trends in Spontaneous Adverse Drug Reaction Reports to the French Pharmacovigilance System (1986—2001) , 2005, Drug safety.

[27]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[28]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[29]  C. Furberg,et al.  Thiazolidinediones and Heart Failure , 2007, Diabetes Care.